CBC, SGOT, SGPT and Creatinine Test in Delhi

CBC + SGOT + SGPT + Creatinine Test at Home

The CBC + SGOT + SGPT + Creatinine panel combines a complete blood count with the two most clinically significant liver transaminases and the single most widely used kidney filtration marker. Rather than a broad multi-organ screen, this is a targeted combination, specifically designed for situations where the clinical question is whether the liver cells are being damaged and whether the kidneys are filtering adequately, both assessed alongside a full blood picture.

The combination is particularly useful in medication safety monitoring. A large number of commonly prescribed drugs, including NSAIDs, methotrexate, antiretrovirals, antimalarials, antifungals, and certain antibiotics, carry known risks of hepatocellular injury (detectable through SGOT and SGPT) and nephrotoxicity (detectable through creatinine), while simultaneously suppressing bone marrow function (detectable through CBC). Monitoring all four markers from a single blood draw gives the prescribing clinician a simultaneous liver, kidney and blood safety profile at each review.

MAX@Home brings this panel to your doorstep. A certified phlebotomist collects your blood sample at home, and the results are available from a partner NABL-accredited laboratory as a digital authenticated report within 24 to 48 hours.

What SGOT and SGPT Measure

SGOT and SGPT are the traditional Indian clinical nomenclature for the same enzymes that international laboratories label AST and ALT respectively. SGOT stands for Serum Glutamic Oxaloacetic Transaminase (AST-aspartate aminotransferase); SGPT stands for Serum Glutamic Pyruvic Transaminase (ALT - alanine aminotransferase). Both names remain in common clinical and colloquial use in India, and most Indian laboratory reports carry both the abbreviation and the international name.

SGPT (ALT): the liver-specific signal

SGPT is the more liver-specific of the two enzymes. It is found predominantly in hepatocytes, the main functional cells of the liver, and is released into the bloodstream when these cells are damaged or destroyed. A rise in SGPT almost always points to the liver as the source of injury, which makes it the preferred single screening marker for hepatocellular damage.

Normal SGPT is below 56 U/L for men and below 36 U/L for women, though reference ranges vary slightly by laboratory. Causes of elevated SGPT include viral hepatitis (hepatitis A, B, C, and E), non-alcoholic fatty liver disease (NAFLD), alcoholic hepatitis, drug-induced liver injury, autoimmune hepatitis, and ischaemic hepatitis from heart failure or shock. In mild NAFLD, SGPT is often the only abnormal liver enzyme, making it a sensitive early warning marker.

SGOT (AST): the broader tissue injury signal

SGOT is present in the liver b,ardiac muscle, skeletal muscle, kidneys, brain, nd red blood cells. Because of this wider tissue distribution, an elevated SGOT is less specific to the liver than SGPT. However, the SGOT:SGPT ratio, the AST:ALT ratio, carries significant diagnostic value once transaminase elevation is confirmed.

A ratio below 1 (SGPT higher than SGOT) is characteristic of viral hepatitis and NAFLD. A ratio above 2:1 (SGOT more than twice SGPT) is a well-established feature of alcoholic liver disease; this reflects the fact that alcohol preferentially damages mitochondria within hepatocytes, where SGOT is concentrated. A very high SGOT with a high ratio in a patient not drinking alcohol prompts evaluation of non-hepatic sources: acute myocardial infarction, rhabdomyolysis, or haemolysis can all produce dramatic SGOT elevations with minimal SGPT change.

Degree of elevation and what it suggests

The scale of transaminase elevation guides urgency. Mild elevation, up to three times the upper limit of normal, is common and may reflect NAFLD, subclinical alcohol use, thyroid disease, coeliac disease, strenuous exercise, or medication effect. Moderate elevation, three to ten times normal, is seen in acute viral hepatitis, significant drug injury, or autoimmune hepatitis flare and typically warrants further investigation. Severe elevation, above ten times normal, is seen in acute hepatocellular necrosis from toxins, ischaemic hepatitis, or fulminant viral hepatitis and is a medical emergency.

When SGOT and SGPT return to normal

In acute hepatitis A or E, transaminases peak early and return to normal over four to eight weeks as the infection resolves. In hepatitis B, normalisation of transaminases signals either clearance of the infection or transition to an immune-tolerant carrier state and must be interpreted alongside hepatitis B  surface antigen and viral load. In drug-induced liver injury, transaminases typically fall once the offending drug is stopped, though the rate of normalisation varies. In NAFLD, transaminases may fluctuate over months and may normalise with weight loss without reflecting complete resolution of hepatic steatosis.

What CBC Measures in This Context

The CBC in this panel serves two distinct purposes alongside the liver and kidney markers.

Detecting haematological toxicity from medications

Many of the medications that require SGOT, SGPT, and creatinine monitoring also suppress bone marrow function. Methotrexate, azathioprine, mycophenolate mofetil, hydroxychloroquine, hydroxyurea, and certain antiretrovirals can reduce haemoglobin, WBC, or platelets, effects that appear on the CBC before symptoms develop. Monitoring CBC alongside liver and kidney markers at every drug safety review is standard practice because drug-induced cytopaenia may precede or coincide with hepatotoxicity or nephrotoxicity, and the combination flags this multi-system effect simultaneously.

Anaemia patterns associated with liver and kidney disease

Chronic liver disease produces several forms of anaemia visible on CBC. Hypersplenism from portal hypertension causes thrombocytopaenia and sometimes pancytopaenia. Chronic alcohol use causes macrocytosis, large red cells due to direct toxic effect on red cell membranes and folate deficiency. Haemolysis from liver disease causes indirect hyperbilirubinaemia in the LFT alongside low haemoglobin and elevated reticulocytes in the CBC. CKD detected through elevated creatinine causes normocytic normochromic anaemia from erythropoietin deficiency. These patterns allow the clinician to use the CBC both as an independent screen and as a validator of the liver and kidney findings.

What Creatinine Measures

Serum creatinine is the single most widely used marker of kidney filtration. It is a metabolic byproduct of phosphocreatine breakdown in muscle, produced at a relatively constant rate and cleared exclusively by glomerular filtration. When the glomerular filtration rate (GFR) falls, creatinine accumulates in the blood proportionally.

The creatinine-eGFR relationship

Creatinine alone is an imperfect filtration marker because its normal range varies with muscle mass, age, and sex; a muscular young man has a higher normal creatinine than a frail elderly woman, even with identical kidney function. The eGFR calculation (estimated GFR derived from creatinine, age, sex, and race) converts creatinine into a standardised kidney function estimate in mL/min/1.73m², making it comparable across different body types. Most modern laboratory reports automatically calculate and report eGFR alongside creatinine, and MAX@Home reports include this derived value.

Creatinine in the context of liver disease

Elevated creatinine in a patient with liver disease has additional diagnostic significance beyond routine renal impairment. Hepatorenal syndrome (HRS) is a form of functional renal failure that develops in patients with advanced cirrhosis and portal hypertension, where systemic vasodilation causes renal vasoconstriction and a progressive rise in creatinine despite the absence of structural kidney damage. It carries a poor prognosis without treatment and is a recognized reason to measure creatinine alongside liver markers, even in patients with no prior history of kidney disease. Early detection through this combined panel gives clinicians the opportunity to manage the precipitating cause (often infection or dehydration) before HRS becomes established.

Creatinine and nephrotoxic medications

Several medications monitored for hepatotoxicity through SGOT and SGPT also carry nephrotoxic risk. NSAIDs cause renal vasoconstriction, particularly in volume-depleted patients or those with pre-existing renal impairment. Aminoglycosides, amphotericin B, and certain antivirals (notably tenofovir) are directly nephrotoxic. Contrast agents used in radiological procedures transiently raise creatinine in predisposed patients. Tracking creatinine alongside liver enzymes ensures that drug-related renal injury is not missed while attention is focused on hepatic effects.

Conditions This Panel Evaluates

Medication Safety Monitoring

Monitoring patients on hepatotoxic and nephrotoxic medications, including methotrexate for rheumatoid arthritis or psoriasis, NSAIDs for musculoskeletal pain, antiretroviral therapy for HIV, antimalarials for lupus, and antifungals for chronic fungal infections, is the most common reason this specific four-marker combination is ordered. Each drug in these categories has defined safe monitoring intervals, and the CBC + SGOT + SGPT + Creatinine panel provides the minimum surveillance dataset in a single home collection.

Viral Hepatitis - Acute and Chronic

Acute viral hepatitis A, B, C, and E all cause marked elevations in SGOT and SGPT, often rising to ten to fifty times normal in the acute phase. Monitoring transaminase normalisation gives clinicians confidence that infection is resolving in self-limiting forms (hepatitis A, E) and helps define the transition from acute to chronic infection in hepatitis B and C. The CBC in the same report checks for haematological involvement - some viral infections, particularly hepatitis C, can cause immune-mediated thrombocytopaenia.

Non-Alcoholic Fatty Liver Disease (NAFLD) and NASH

NAFLD is present in an estimated 25 to 30 percent of Indian adults, and in a much higher proportion of those with obesity, type 2 diabetes, or metabolic syndrome. The majority have no symptoms. Mildly elevated SGPT with a normal or near-normal SGOT and a normal bilirubin and albumin is the characteristic finding in simple hepatic steatosis. When SGOT begins to approach or exceed SGPT, it may signal progression from simple steatosis to non-alcoholic steatohepatitis (NASH), which carries a significant fibrosis risk. Serial monitoring with this panel tracks disease course and treatment response.

Alcoholic Liver Disease

Alcoholic liver disease is detected through the characteristic pattern of SGOT:SGPT ratio above 2:1, typically with both values in the moderate elevation range (three to eight times normal) rather than the extreme elevations of viral hepatitis. Elevated GGT (usually measured in a broader LFT panel) and macrocytosis on the CBC (from alcohol's direct effect on erythropoiesis and folate depletion) further support the diagnosis. The creatinine in the same draw checks for the renal tubular acidosis and dehydration that commonly accompany heavy alcohol use.

Who Should Get This Test

• Patients on methotrexate, NSAIDs, antiretrovirals, antimalarials, antifungals, or other medications requiring hepatic and renal safety monitoring.
• Individuals with known or suspected viral hepatitis B or C being monitored for disease activity or treatment response.
• Those with NAFLD or alcoholic liver disease under surveillance for disease progression.
• Patients with pre-existing kidney disease where transaminase monitoring is also clinically indicated.
• Adults with fatigue, right upper abdominal discomfort, or jaundice requiring initial multi-system evaluation.
• Those who want a compact liver-blood-kidney screen without the full LFT panel.

How to Prepare for the Test

Fasting

An eight to ten hour fast before the test is recommended. SGPT and SGOT are not significantly affected by food intake, but fasting ensures consistency with co-ordered tests and avoids any transient dietary lipid elevation in the serum that can occasionally interfere with certain laboratory assays.

Before your phlebotomist arrives

• Tell the phlebotomist if you have any active infection, recent surgical procedure, or new medication started in the past two weeks; all of these can acutely affect transaminases and creatinine.
• Avoid intense exercise for 24 hours. Vigorous physical activity releases SGOT from skeletal muscle and can elevate creatinine from muscle protein catabolism.
• Do not stop any medications before the test unless your doctor has specifically directed this. The purpose of monitoring is to see your markers on your current treatment.
• Tell the phlebotomist if you have any active infection, recent surgical procedure, or new medication started in the past two weeks - all of these can acutely affect transaminases and creatinine.

How to Book with MAX@Home

Booking this four-marker panel at home with MAX@Home takes minutes.

1.  Visit the MAX@Home website or call the helpline and select the CBC + SGOT + SGPT + Creatinine panel.

2.  Choose a morning fasting slot that suits your schedule.

3.  A certified phlebotomist arrives at your home with sterile equipment.

4.  A single venous blood draw collects the sample for all four tests.

5.  Samples are transported to a partner NABL-accredited laboratory under appropriate chain-of-custody conditions.

6.  Your digital authenticated report is delivered within 24 to 48 hours to your registered contact.